Cleveland BioLabs, Inc. (NASDAQ:CBLI) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.50) EPS for the quarter, Bloomberg Earnings reports. Cleveland BioLabs had a negative net margin of 111.40% and a negative return on equity of 28.45%. The business had revenue of $0.21 million during the quarter.

Shares of Cleveland BioLabs (NASDAQ:CBLI) opened at 2.70 on Tuesday. The firm has a 50-day moving average price of $2.76 and a 200 day moving average price of $2.63. Cleveland BioLabs has a one year low of $1.22 and a one year high of $5.55. The firm’s market capitalization is $30.45 million.

Separately, ValuEngine raised Cleveland BioLabs from a “sell” rating to a “hold” rating in a report on Friday.

A hedge fund recently raised its stake in Cleveland BioLabs stock. Vanguard Group Inc. raised its stake in Cleveland BioLabs, Inc. (NASDAQ:CBLI) by 106.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 170,088 shares of the biotechnology company’s stock after buying an additional 87,885 shares during the period. Vanguard Group Inc. owned about 1.51% of Cleveland BioLabs worth $501,000 as of its most recent filing with the SEC. 1.70% of the stock is owned by institutional investors.

WARNING: “Cleveland BioLabs, Inc. (CBLI) Announces Quarterly Earnings Results” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.watchlistnews.com/cleveland-biolabs-inc-cbli-announces-quarterly-earnings-results/1490115.html.

About Cleveland BioLabs

Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.

Earnings History for Cleveland BioLabs (NASDAQ:CBLI)

Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.